Prof. Dr. Andreas Zirlik, FESC, FACC
Klinik für Kardiologie und Angiologie I Universitäts-Herzzentrum Freiburg – Bad Krozingen
Date of Birth: 22nd January 1974 in Schweinfurt, Germany
Training and academic degrees:
| 1984-1993 | Grammar school “Celtis Gymnasium”, Schweinfurt, Germany. Final exam (Abitur) with an average of 1.0. Scholarship of the Bavarian State for highly talented students („Bayerische Bayerischen Hochbegabtenprüfung“). |
| 11/1993-11/1999 | Medical Studies at the University of Leipzig, Germany. Trimesters at the
University of Alabama, Birmingham, USA, and the University of Montpellier, France. Final medical exam (3. Staatsexamen) with an average of 1.0 |
| 11/1999 | State medical license (Approbation) |
| 11/2001 | Academic degree “Dr. med.” with “summa cum laude” from University of Leipzig, Leipzig, Germany |
| 10/2008 | State Board („Facharzt“) for Internal Medicine (WBO 2003) |
| 12/2009 | Habilitation on the topic „Modulation of inflammatory signaling pathways as therapeutic target in atherosclerosis“, Venia legendi for Internal Medicine/Cardiology |
| 08/2012 | State Board („Facharzt“) for Internal Medicine and Cardiology (WBO 2006) |
| 10/2012 | Professor for Medicine/Cardiology of the Medical Faculty of the University of Freiburg, Germany |
| 03/2015 | Listing in the appointment procedure for the Chief of Cardiology and University
Professorship/Ordinariat („W3 Professor“) Internal Medicine/ Cardiology at the University of Jena, Germany |
| 03/2015 | Designated President of the German Society of Atherosclerosis Research (DGAF) |
| 12/2017 | Listing in the appointment procedure for the Chief of Cardiology and University
Professorship/Ordinariat („W3 Professor“) Internal Medicine/ Cardiology at the University of Halle, Germany |
| 03/2018 | Call to the Professorship for Internal Medicine and Cardiology at the University Graz, Austria |
| 04/2018 | President of the German Society of Atherosclerosis Research (DGAF) |
Positions and clinical/academic development:
1/2000-6/2003 Residency in Internal Medicine at the University Hospital of the University of Freiburg, Germany, Department of Cardiology and Angiology (Prof. Dr. Christoph Bode), scientific work on the regulation of the expression of
Plasminogen Activator Inhibitor-1 (PAI-1) in adipose tissue
| 7/2003- 8/2005 | Postdoctoral Fellowship at the Brigham and Women’s Hospital, Cardiovascular Medicine (Prof. Dr. Peter Libby), Harvard Medical School, Boston, USA, scientific work on CD40/CD40L-dependent functions in atherosclerosis |
| 9/2005-3/2009 | Continuation of clinical and scientific work as Fellow in Internal Medicine/Cardiology at the University Hospital Freiburg, Germany, Department of Cardiology and Angiology (Prof. Dr. Christoph Bode), scientific work on inflammatory signaling pathways in atherosclerosis and metabolic syndrome |
| Since 9/2005 | Principal Investigator/Leader of the Atherogenesis Research Group Freiburg with currently 2 medical technicians, 1 junior group leader, 4 Post-Docs, 2 PhD student and 3 MD students |
| Since 4/2009 | Attending/Consultant („Oberarzt“) in Internal Medicine/Cardiology at the
University Hospital Freiburg, Germany, Department of Cardiology and Angiology (Prof. Dr. Christoph Bode, since 4/2012 transformed into the Department of Cardiology/Angiology at the University Heart Center Freiburg • Bad Krozingen) |
| Since 2/2013 | Deputy Medical Director of the Department of Cardiology and Angiology I of the University Heart Center Freiburg (Prof. Dr. Christoph Bode) with full clinical and administrative authorities |
Clinical Responsibilities and interventional performance numbers:
| Since 08/2009 | Head of the Heart Failure and Heart Transplantation Unit | |
| Since 01/2010 | Member of the 24h PCI team of Attendings/Consultants | |
| Since 10/2010 | Head of the Interventional Valve Team (ISAH), specialized on Mitraclip implantations | |
| Since 01/2011 | Member of the 24h on call team of Attendings/Consultants for the ICU | |
| Since 08/2011 | Head of the Interventional Hypertensiology/Renal Denervation Unit | |
| Since 02/2013 | Research Coordinator of the Department | |
| Since 10/2016
|
Head of the cardiovascular high risk outpatient service | |
| >4000 | Left Heart Catheterizations and PCIs | |
| >500 | Right Heart Catheterizations | |
| >200 | Myocardial Biopsies | |
| >150 | Renal Denervations | |
| >150 | Mitraclip Implantations | |
| >100 | ECLS and Impella Implantations | |
| >50 | Pericardiocentises | |
| >40 | TAVI | |
| >15
|
CardioMEMS Implantations | |
| Prizes and Awards:
|
||
| 1993-1999 | Scholarship of the Bavarian State for highly talented students after passing the
High Talent Exam („Hochbegabtenprüfung“), approx. 70.000,- DM in 6 years |
|
| 10/1998 | „Wolfgang-Natonek-Award“ for outstanding study results and special dedication for students’ interests by the Association of Sponsors and Friends of the University of Leipzig, 5,000.- DM | |
| 7/2003-6/2004 | Research Fellowship by the German Research Foundation („Deutsche Forschungsgemeinschaft“). Topic: The role of CD40-deficiency in atheromaassociated endothelial cells, smooth muscle cells, and monocytes/macrophages with special respect to cell type-specific signaling functions, DFG-ZI-743/1-1, approx. 35,000.- Euro | |
9/2005 -7/2006 Returning from Post-Doc Fellowship by the Medical Faculty of the University of Freiburg, approx. 30,000.- Euro
12/2007 MSD Award for Atherosclerosis/Hypertension 2007, 10,000.- Euro
2018 Albert-Fraenkel-Prize of the German Cardiac Society (DGK), 5.200,- Euro
Patents:
17.08.2011 European Patent Application on „Selective Targeting of the CD40L/Mac-1
interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis” (PCT/EP2011/064132 (WO2012005225 A1))
21.06.2016 European Patent Application on “Antibodies for the selective inhibition of inflammation and pharmaceutical compositions containing such antibodies (EP 16175382.7)
Teaching/ Lecturing Experience:
| 1993-1999 | As MD student leader of newly founded POL (Problem oriented Lerning)
Groups, student representative in various academic and university committees (Faculty Board, Senate, Konzil, Appointment Committees for Professors) |
|
| 1/2000- 6/2003 | Clinical Examination Courses in Internal Medicine | |
| Since 2005 | Various Courses and Lectures Internal Medicine and Cardiology (e.g., Bedside
Teaching, Differential Diagnostics of Thoracic Pain, Syncope, Casuistics) |
|
| Since 2009 | Pathophysiology Lecture (Heart Failure, Atherosclerosis), Main Lecture in Internal Medicine (Acute Coronary Syndrome, Heart Failure, Heart Transplantation, Hypertension), Lecture Molecular Cardiology (Inflammatory mechanisms in atherosclerosis, myocardial infarction, and metabolic syndrome) | |
| Since 2010 | Member of the Faculty of the International Master Program in Biomedical
Sciences (IMBS), a joint Master/PhD program of the University of Buenos Aires, Argentina and the University of Freiburg, Germany |
|
| Since 2013 | Head of the Internal Medicine Module of the Molecular Medicine Study
Program (Prof. Dr. Christoph Peters) of the University of Freiburg |
Mentoring:
- Mentoring of doctoral theses after my Habilitation:
- a) Medical doctoral theses:
Isabel Amelie Platzer CD40L induces inflammation in adipose tissue – a potential link between atherosclerosis and metabolic syndrome?
2010, magna cum laude
Benjamin Josef Sommer Analysis of the expression of Tumor Necrosis Factor Receptor-associated factors in blood of patients with coronary heart disease
2010, magna cum laude
| Natascha Köstlin | Tumor Necrosis Factor Receptor-associated factor-1 (TRAF1) and its role in the pathogenesis of atherosclerosis
2010, summa cum laude |
| Peter Stachon | The role of TRAF2 and TRAF6 in atherogenesis
2010, summa cum laude |
| Philipp Rudolf | TRAF5-deficiency promotes atherogenesis in mice by increased recruitment of inflammatory cells and foam cell formation |
2011, summa cum laude
| Katharina Zeschky | The Cannabinoid Receptor 2 (CB2) does not modulate the development of atherosclerosis in mice
2012 magna cum laude |
| Dennis Wolf | Descriptive and functional characterization of the CD40L/Mac-1 interaction
2012, summa cum laude |
| Carina Verena Walter | TRAFIC – a prospective study of the expression of tumor necrosis factor receptor-associated factors in patients with coronary heart disease
2012, magna cum laude |
| Imke Ilina Remer | Syk inhibition by fostamatinib reduces macrophage accumulation in atherosclerotic plaques 2013, magna cum laude |
| Eva Nora Bukosza | Contribution of the CD40L/Mac-1 pathway to the metabolic syndrome |
2013, magna cum laude
Johanna Maria Maxeiner The role of microRNA-206 in skeletal muscle regeneration and the pathogenesis
of Duchenne muscular dystrophy, abgeleistet im Labor von Prof. Olson am UT
Southwestern Medical Center, Dallas, USA
2013, magna cum laude
| Felix Jehle | The role of CD40L and its receptor CD40 in the pathogenesis of the metabolic syndrome
2014, summa cum laude |
| Sara Eisele | Syk inhibition limits atherogensis in mice
2014, magna cum laude |
| Louisa Gerhard | Ly6Chigh monocytes promote the bisphasic healing after experimental myocardial infarction via Nr4a1
2014, summa cum laude |
| Shilpa Tiwari | The role of CD40L and its receptors in neointima formation in mice
2015, summa cum laude |
| Alexander Peikert | The role of P2Y6 in murine atherosclerosis
2016, summa cum laude |
| Ansagar Wiedemann | Pro-inflammatory functions of the CD40L-Mac-1 interaction 2016, magna cum laude
b) PhD theses (Biology, Pharmacology): |
| Dr. med. Anna Missiou
Alexandra |
The role of Tumor Necrosis-Factor-Receptor-Associated Factors (TRAF) 1,5, and 6 in atherosclerosis 2010, magna cum laude |
| Ortiz-Rodrigues | A specific antibody to the CD40L/Mac-1 interaction limits myocardial infarction in mice
2016, magna cum laude |
| Nathaly Anto Michel | Genetic deficiency of TRAF-1 attenuates diet-induced adipose tissue inflammation by limiting the pool of circulating and splenic monocytes in mice |
2017, magna cum laude
- Ongoing mentoring of doctoral theses:
- a) MD theses:
| Christian Colberg | Differential cell type-specific expression of Tumor Necrosis Factor-associated
Factors in murine atherosclerosis and diet-induced obesity, ongoing |
|
| Benjamin Ruppert | Modulation of the neointima formation by RNAse, ongoing | |
| Lisa Schulte | The effect of renal denervation on inflammatory markers and cell populations, ongoing | |
| Katharina Gutte | TRAF1-deficiency modulates platelet function, ongoing | |
| Markus Jäckel | The role of CD40L-dependent signaling pathways in acute myocardial infarction in mice, ongoing | |
| Alexandra Lindau | Syk inhibition with fortamatinib in established atherosclerosis, ongoing | |
| Sejosha Geis | The role of P2X7 in murine atherogenesis, ongoing | |
| Adrian Heidenreich | The contribution of P2Y2 to de novo atherosclerosis, ongoing | |
| Philipp Albrecht | The role of P2Y2 in diet-induced obesity in mice, ongoing | |
| Fathi Ünal | Contribution of the purinergic receptor P2Y6 to the metabolic syndrome, ongoing | |
| Colin Gissler | The role of TRAF5 in diet-induced obesity, ongoing | |
| Philipp Scherrer | The role of CD40L in endothelial cells in Atherogenesis, ongoing | |
| Jan Pennig | Hyperglycemia as a regulator of ApoC-III and Atherosclerosis, ongoing | |
| Xia Sheng | Immunologic predictors of human atherosclerosis, ongoing | |
| Marwa Ahmed Salem | Baroreceptor stimulation vs. renal denervation in therapy-refractory hypertension – a indirect comparison, ongoing | |
| Ibrahim Hassanin | The role of P2Y6 receptors for the acute myokardiale infarction in mice, ongoing | |
| Lisa Beiner | Characterization of Syk in myokardiale infarction in mice, ongoing | |
| Sunaina von Garlen | P2X7 in myokardiale infarction, ongoing | |
| Haitham Saifeldeen | Comparison of wide and narrow circumferential antral pulmonary vein isolation in paroxysmal and persistent atrial fibrillation, ongoing | |
| Katharina Pfeiffer
|
Atherosclerosis progression and – regression induced through Antisense oligo nucleotides in mice, ongoing
b) PhD theses: |
|
| Julian Merz | The role of purinergic signaling in experimental myocardial infarction, ongoing | |
- Mentoring of Diploma-, Master-, and Bachelor theses:
| Natalie Regina Stickel | The differential role of dendritic cells in experimental autoimmune myocarditis
Diploma thesis Molecular Medicine, 2011, Mark 1.0 |
| Carla Winter | Is homing of the spleen and recruitment from spleen Syk-dependent?
Bachelor Thesis Molecular Medicine, 2012, Mark 1.3 |
| Nathaly Anto Michel | Characterization of a novel antibody targeting the CD40L/Mac-1 interaction in vascular disease
IMBS Master Thesis, 2012, 12/12 Points |
| Leandro Nieto | The role of Syk kinase in progression of murine atherosclerosis
IMBS Master Thesis, 2013, 11/12 Points |
- Prizes, Stipends und Third Party Funding of mentored members of the Atherogenesis Research Group:
2007-2008 Dr. Dennis Wolf, Carl-Duisberg-Stipend of the Bayer Science and Education
Foundation, 9,150.- Euro
- Dennis Wolf, Poster Prize at the Annual Meeting of the Australian-New
Zealand Society of Cardiology (CSANZ) in Adelaide, Australien, 500.- USD
- med. Felix Jehle, Boehringer Ingelheim-Stipend „The role of CD40L in adipose tissue – implications for atherosclerosis and the metabolic syndrome, 7,200.- Euro
- med. Felix Jehle, DAAD Stipend, approx. 5,000.- Euro
2009-2010 cand. med. Felix Jehle, Stipend of the Ernst Solway Foundation, approx.
10,000.- Euro
- Dennis Wolf, ATVB Scientific Sessions Travel Awards for Young
Investigators der American Heart Association (AHA), 500.- USD
- Dennis Wolf, Best Abstract Award, Annual Meeting of the German Society of Thrombosis and Hemostaseology (GTH), 500.- Euro
2011 Dr. Dennis Wolf, Young Investigator Award of the European Society of
Cardiology (ESC) for „Selective Disruption of the CD40L/Mac-1 Interaction by a Small Peptide Inhibitor Mimicking the EQLKKSKTL Motif Attenuates Inflammation and Atherogenesis in Mice”, 5,000.- Euro
2011 cand.med. Christian Colberg, PROMOS-Stipend “Function und Regulation of microRNA-880 by CD40 in the Metabolic Syndrome“, approx. 8,500.- Euro
- med. Christian Colberg, Kaltenbach Stipend of the German Cardiac
Foundation, approx. 5,000.- Euro
- Ingo Hilgendorf, DFG-Fellowship at the Center for Systems Biology,
Laboratory of Prof. Filip K Swirski, MGH and Harvard Medical School, Boston, MA, USA (HI 1573/1-1), 80,000.- Euro
- Dennis Wolf, Poster Award athe the Annual Meeting of the German Society for Thrombosis and Haemostaseology (GTH) on “Genetic deficiency of CD40L attenuates diet-induced adipose tissue inflammation – but does not protect from insulin resistance and hepatic steatosis in mice“, 500.- Euro
- Florian Willecke, DFG-Fellowship at the Columbia University, Laboratory of Prof. Dr. Ira Goldberg, New York, NY, USA (WI 4064/1-1), 72,000.- Euro
- Dennis Wolf, Wilhelm-Stoffel Stipend for Atherosclerosis Research (MSD
Sharp & Dome), 15,000.- Euro
2013 Dr. Dennis Wolf, Inge-Edler-Stipend of the German Society of Cardiology
(DGK), 25,000.- Euro
- Dennis Wolf, Young Investigator Award of the Germany Society of Atherosclerosis Research (DGAF) on “Co-stimulatory signaling through lymphocyte CD40 limits adipose tissue inflammation and protects from de novo and pre-established metabolic disease in mice, 2,500.- Euro
2013-2014 Dr. Ingo Hilgendorf, Rudolf-Marx Stipend of the German Society of
Thrombosis and Hemostaseology (GTH), 16,000.- Euro
2013-2014 Markus Jäckel, MOTIVATE dissertation stipend of the Else-Kröner-Fresenius
Foundation, 7,200.- Euro
- Louisa Gerhard, DGK-Otto-Hess-Stipend of the German Society of Cardiology (DGK), 12×500.- Euro
2014 Dr. Ingo Hilgendorf, Emmy-Noether-Program of the German Research
Foundation (DFG), 1.4 Mio Euro for 5 years (HI 1573/2-1)
- Peter Stachon, Best Abstract Award, Jahrestagung der Deutschen Gesellschaft für Thrombose und Hämostaseologie (GTH), Wien, 500.- Euro
- Louisa Gerhard, DGK-Otto-Hess-Poster Award at the Annual Meeting of the
German Society of Cardiology (DGK), 1,500.- Euro
2015 Dr. Peter Stachon, Best Abstract Award, Jahrestagung der Deutschen Gesellschaft für Thrombose und Hämostaseologie (GTH), Düsseldorf, 500.- Euro
2015 Dr. Ingo Hilgendorf, W.H. Hauss Award of the German Society of
Atherosclerosis Research (DGAF), 2,500.- Euro
- Dennis Wolf, Research Prize of the Acute Cardiovascular Care Association, Annual ACCA Meeting Vienna, 3,000.- Euro
- Ingo Hilgendorf, Oskar-Lapp-Stipendium der Deutschen Gesellschaft für
Kardiologie, Jahrestagung in Mannheim 2016, 20,000.- Euro
2016 Alexander Peikert, Edith von Kaulla research prize, Medical Faculty of the
Albert-Ludwigs-University, Freiburg, 20,000.- Euro
Academic Activities:
- a) Membership in Clinical and Scientific Associations
Since 2001 Member of the German Association of Cardiology (DKG)
Since 2001 Member of the European Society of Cardiology (ESC)
Since 2002 Member of the German Society of Atherosclerosis Research (DGAF)
Since 2004 Member of the American Heart Association (AHA)
Since 2011 Member of the International Society for Heart and Lung Transplantation (ISHLT)
Since 2011 Member of the Society of Thrombosis and Hemostaseology (GTH)
Since 2013 Fellow of the European Society of Cardiology (FESC)
Since 2013 Member of the German Society of Internal Medicine (DGIM)
Since 2014 Fellow of the American College of Cardiology (FACC)
Since 2016 Member of the Southwest German Society for Internal Medicine (SwGIM)
Since 2017 Member of the European Atherosclerosis Society (EAS)
Since 2017 Fellow of the American Heart Association (FAHA)
- Reviewer for Scientific Journals
Since 2003 ad hoc reviewer for Thrombosis Heamostasis, Heart
Since 2006 ad hoc reviewer for ATVB, British Journal Haematology, Circulation
Since 2008 ad hoc reviewer for Atherosclersosis, American Heart Journal
Since 2009 ad hoc reviewer for American Journal Cardiology
Since 2010 ad hoc reviewer for PLoS One, Circulation Research
Since 2012 ad hoc reviewer for European Journal of Endocrinology, Hypertension
Since 2013 ad hoc reviewer for Experimental Physiology, Cardiovascular Diabetology,
Clinical Research in Cardiology, Arthritis Research and Therapy
Since 2014 ad hoc reviewer für FEBS Journal, Hämostaseologie
- Special Academic Activities:
2007-2011 Member of the Board of Principle Investigators of the Speman Graduate School of Biology and Medicine, Excellence Initiative of the German Research Foundation (DFG)
Since 2010 Member of the Faculty of the International Master Program in Biomedical
Sciences (IMBS), a joint Master/PhD Program of the University of Buenos Aires, Argentina nad the University of Freiburg, Germany
Since 2010 Member of the Local Editorial Team of the European Editor of Circulation, Prof. Dr. Christoph Bode
Since 2010 Organization of the Summer School of the Department, a scientific retreat
(approx. 80-100 participants)
Since 2011 Editorial Board Member of Case Reports in Vascular Medicine
Since 2012 Editorial Board Member of PlosOne (IF 3.5)
Since 2012 Ad hoc reviewer for the German Science Foundation (DFG), member of the review committee of SFB688
| 2012-2015 | Member of the Advisory Board of the German Society of Atherosclersis Research (DGAF) |
| Since 2013 | Member of the Steering Committee of the Pre-TRUST Study (Trial of Ularitide for the prevention of renal worsening in patients at risk for radiocontrast induced nephropathy), Sponsor Cardiorentis AG, Zug, Schweiz |
| 2013-2015 | Congress Secretary of the Annual Meeting of the Soviety of Thrombosis and Hemasteseology (GTH) in 2015 in Düsseldorf (Congress Presidents: Profs. Bode und Scharf) |
| Since 2015 | Designated President of the German Society of Atherosclerosis Research (DGAF) |
| Since 2016 | Co-chairman of the working group “Heart and Diabetes” (AG23) of the German Cardiac Society (DGK) |
| Since 2017 | Editor of the German Journal “Cardiology up2date” |
| Since 12/2017 | Editorial Board Member of Atherosclerosis |
| Since 2018 | President of the German Society of Atherosclerosis Research (DGAF) |
Acquisition of Third Party Funding:
| a) Project Funding: | |
| 2006-2008 | Grant of the German Research Foundation (DFG): The role of Tumor Necrosis Factor Receptor-Associated Factors in Atherosclerosis, DFG-ZI-743/3-1, approx. 280,000.- Euro |
| 2007-2009 | Scientific cooperation with Boehringer Ingelheim, Ridgefield, CT, USA: The role of sEH Inhibitors in Atherosclerosis, approx. 100,000.- Euro |
| 2010-2012 | Succession Grant of the DFG on the role of Tumor Necrosis Factor Receptor-
Associated Factors in Atherosclerosis, DFG-ZI-743/3-2, approx. 140,000.- Euro |
| 2010-2012 | Grant of the Else-Kröner-Fresenius Foundation: Therapeutic targeting of the
CD40L/Mac-1 dyad as potential treatment for atherosclerosis, EKFS P30/10//A43/10, 130,000.- Euro |
| Since 2012 | Grant of the Fritz Thyssen Foundation: Investigation of CD40L-associated genes and their functional contribution to the pathogenesis of the metabolic syndrome – studies in mice and men, Az. 10.11.1.228, 110,000.- Euro |
| Since 2012
|
Scientific Cooperation with ResMed, Bella Vista, New South Wales, Australia: Influence of high-intensity non-invasive positive pressure ventilation on systemic inflammation and predictors of cardiovascular risk in patients suffering from stable hypercapnic chronic obstructive disease (COPD)” together with PD Dr. Michael Dreher, approx. 90,000.- Euro |
| Since 2012 | Scientific Cooperation with Astra Zeneca, Gothenburg, Sweden: The role of Syk
Inhibition in Atherosclerosis, 135,000.- Euro |
| Since 2014 | Start up grant of the Medical Faculty of the University of Freiburg for a BmBf project: ACS-AF-short, 35,000.- Euro |
| Since 2015 | Cooperation project „The Role of CD40 in Endothelial and Smooth Muscle Cell on Atherogenesis” mit LMU München, Institute for Cardiovascular Prevention (IPEK, Prof. Dr. C. Weber) under the framework of the German Center for Cardiovascular Research (DHZK), 10,000.- Euro |
| Since 2015 | Currently two new research grant proposals under review with the German
Research Foundation (ZI743/5-1 und 6-1) |
| Since 2016 | Grant of the German Research Foundation (DFG): Extracellular ATP and purinergic receptors in Atherosclerosis (ZI 743/7-1), 381,000.- Euro |
| Since 2016 | Research grant from the GTH (Society of Thrombosis and Hemostaseology), “Expression of TRAF1 on thrombocytes and their role in Atherosclerosis“, 50.000,- Euro |
| Since 2017
|
Grant of the German Research Foundation (DFG): Tyrosinkinase Syk: A possible target for Atherosclerosis (ZI 743/8-1), 346,100.- Euro
b) Clinical Studies: |
| 2009-2012 | RUBY-1, Indication: ACS, Phase II, Role: PI Freiburg, Safety and tolerability of darexaban (YM150) following ACS, Recruitment: 22 patients, approx. 130,000.- Euro |
| 2010-2014 | The Stabilization of plaques using Darapladib – Thrombolysis In Myocardial
Infarction 52 Trial (SOLID-TIMI 52), Indication: ACS, Phase III, Role: PI Freiburg, Recruitment: 16 patients, approx. 95,000.- Euro |
| 2011-2015 | SERVE-HF, Indication: Heart Failure, Phase III, Role: PI Freiburg, Treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure, Recruitment: 8 patients, Sponsor: ResMed, approx. 35,000.- Euro |
| 2011-2015 | SchlaHF Registry, Indication: Heart Failure, Registry, Role: PI Freiburg, Relation between heart Failure and sleep related breathing disorders Recruitment: 106 patients, Status: Follow up, Sponsor: ResMed, approx. 8,000.- Euro |
| 2012-2017 | CANTOS, Indication: Coronary Artery Disease, Phase III, Role: PI Freiburg, The Canakinumab Anti-inflammatory Thrombosis Outcomes Study,
Recruitment: 10 patients, Status: Follow up, Sponsor: Novartis, approx. 60,000.- Euro |
| Since 2013 | GREAT Symplicity Registry, Indication: Hypertension, Registry, Role: PI Freiburg, Real World Renal Denervation, Recruitment: 68 patients, Status:
recruiting, Sponsor: Medtronic, approx. 120,000.- Euro |
| Since 2013 | ODYSSEY, Indication: Coronary Heart Disease, Phase IIII, Role: PI Freiburg,
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab, Recruitment: 25 Patienten, Status: in FU, Sponsor: Sanofi Aventis, approx. 225,000.- Euro |
| 2014-2016 | PM1116197 LATTITUDE, Indication: ACS, Phase III, Role: PI Freiburg, Losmapimod (p38 Inhibitor) vs. Placebo in patients with ACS, Recruitment: 16 patients, Sponsor: Glaxo Smith Kline, approx. 80,000.- Euro |
| Since 2014 | RELAX Study RLX030A, Indication: Heart Failure, Phase III, Role: PI Freiburg, Serelaxin in acute Heart Failure, Status: recruiting, Sponsor: Novartis, approx. 50,000.- Euro |
| Since 2014 | CULPRIT SHOCK, Indication: ACS with cardiogenic shock, Role: PI Freiburg, PCI culprid lesion versus multi vessel PCI in cardiogenic shock, Status: recruiting, Sponsor: BmBf-IIT Prof. Dr. Holger Thiele, approx. 30,000.- Euro |
| Since 2014 | GREAT Symplicity Spyral Addendum, Indication: therapy-refractory hypertension, Phase IV, Role: PI Freiburg, Efficacy of the new Symplicity Spyral Systems, Status: recruiting, Sponsor: Medtronic, approx. 78,000.- Euro |
| Since 2015 | DIGIT-HF, Indication: Heart Failure, Phase IV, Role: PI Freiburg, Digitoxin in patients NYHA III-IV, Sponsor BmBf-IIT PD Dr. Udo Bavendiek, Status:
recruiting, approx. 30,000.- Euro |
| Since 2015 | Report-HF Registry, Heart Failure Registry Indication: Heart Failure, Role: PI
Freiburg, Sponsor: Novartis, Status: recruiting, approx. 234.000.- Euro |
| Since 2016 | ACTIVITY Study, Study on physical activity in patients with heart failure,
Role: PI, Sponsor: Novartis, Status: recruting |
| Since 2016 | PEREGRINE Study, CE Certification Study for new renal denervation concept with micro ethanol injection, Role: PI Freiburg, Status: recruiting, 81,550.- Euro |
| Since 2016 | CardioMEMS Study, European Monitoring Study for Heart Failure, Role: PI Freiburg, Sponsor: St. Jude Medical, Status: recruiting |
| Since 2017 | PARADISE-AMI Study, Role: PI, Sponsor: Novartis, Status: initiation |